Assessment of risk factors responsible for rapid deterioration of lung function over a period of one year in patients with chronic obstructive pulmonary disease.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 06 2021
30 06 2021
Historique:
received:
15
12
2020
accepted:
18
06
2021
entrez:
1
7
2021
pubmed:
2
7
2021
medline:
9
11
2021
Statut:
epublish
Résumé
Compromised lung function is a common feature of COPD patients, but certain factors increase the rate of lung function decline in COPD patients. The objective of the current study was to investigate the effect of different clinically important factors responsible for rapid deterioration of lung function quantified as ≥ 60 ml decline in FEV1 over a period of one year. COPD patients recruited from the chest clinic of Penang hospital were followed-up for one year from August 2018 to August 2019. Rapid deterioration of lung function was defined as greater than 60 ml/year decline in force expiratory volume in one second. Among 367 included patients 73.84% were male, with mean age 65.26 (9.6) years and % predicted FEV
Identifiants
pubmed: 34193949
doi: 10.1038/s41598-021-92968-5
pii: 10.1038/s41598-021-92968-5
pmc: PMC8245547
doi:
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
13578Références
PLoS One. 2018 Mar 26;13(3):e0194983
pubmed: 29579084
Respir Med. 2010 Jun;104(6):773-9
pubmed: 20417082
Am J Respir Crit Care Med. 2016 Jul 15;194(2):178-84
pubmed: 26808615
Pharmacoecon Open. 2021 Mar;5(1):35-44
pubmed: 32291727
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7
pubmed: 12091180
BMJ Open. 2019 Jun 28;9(6):e025776
pubmed: 31256021
Expert Rev Pharmacoecon Outcomes Res. 2019 Oct;19(5):517-528
pubmed: 31401898
COPD. 2019 Feb;16(1):51-57
pubmed: 30917705
COPD. 2016 Aug;13(4):425-30
pubmed: 26807738
Lancet. 2015 May 2;385(9979):1778-1788
pubmed: 25943942
BMC Pulm Med. 2017 Feb 20;17(1):42
pubmed: 28219428
Eur Respir J. 2007 Oct;30(4):616-22
pubmed: 17906084
Thorax. 2010 Oct;65(10):878-83
pubmed: 20729231
Thorax. 2004 May;59(5):387-95
pubmed: 15115864
Am J Respir Crit Care Med. 2011 Nov 1;184(9):1015-21
pubmed: 21836135
Expert Rev Pharmacoecon Outcomes Res. 2020 Dec;20(6):661-672
pubmed: 31596632
Patient Prefer Adherence. 2018 Jan 11;12:97-104
pubmed: 29391781
Eur Respir J. 2005 Nov;26(5):948-68
pubmed: 16264058
Ther Adv Chronic Dis. 2016 Jan;7(1):34-51
pubmed: 26770668
Eur Respir J. 2004 Jan;23(1):28-33
pubmed: 14738227
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Respirology. 2020 Jan;25(1):80-88
pubmed: 31251440
Chest. 2002 May;121(5):1434-40
pubmed: 12006425
Respir Res. 2017 Oct 24;18(1):180
pubmed: 29065892
Am J Respir Crit Care Med. 2014 Nov 1;190(9):996-1002
pubmed: 25172140
Am J Respir Crit Care Med. 2008 Aug 15;178(4):332-8
pubmed: 18511702
N Engl J Med. 2004 Mar 4;350(10):1005-12
pubmed: 14999112
Health Qual Life Outcomes. 2020 May 13;18(1):138
pubmed: 32404113
Thorax. 2019 Jul;74(7):650-658
pubmed: 31028237
Am J Respir Crit Care Med. 1995 Sep;152(3):1107-36
pubmed: 7663792
Respirology. 2016 Jan;21(1):14-23
pubmed: 26494423
Respir Med. 2010 Jun;104(6):849-57
pubmed: 20471236
Am J Respir Crit Care Med. 2012 Jan 1;185(1):44-52
pubmed: 22016444
Eur J Health Econ. 2020 Mar;21(2):181-194
pubmed: 31564007
Chest. 2008 Jan;133(1):19-25
pubmed: 17908709
Thorax. 2019 May;74(5):439-446
pubmed: 30617161
Eur Respir J. 2011 Jul;38(1):29-35
pubmed: 21565915
J Clin Epidemiol. 2014 Aug;67(8):904-11
pubmed: 24786594
Am J Respir Crit Care Med. 2017 Feb 1;195(3):324-330
pubmed: 27556408